Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethambutol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.94 |
| ▸ | CNR1 | P21554 | 1/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethambutol SCHEMBL3398 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL27583822 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL3026481 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL650049 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL37049 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL9949005 | 1.00 | ABCC3 (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL2636850 | 0.97 | LMNA (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL15479016 | 0.97 | LMNA (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL3399 | 0.97 | LMNA (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A | |
| Ethambutol SCHEMBL2961583 | 0.97 | LMNA (1.00) | ABCC3SMN1; SMN2LMNACNR1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3712 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119246737-B | Method for simultaneously determining (+) -2-aminobutanol and ethambutol hydrochloride based on RP-HPLC-NQAD method | 浙江省食品药品检验研究院 | 2025-02-11 | — | — | CN | claimed |
| CN-119246737-A | Method for simultaneously determining (+) -2-aminobutanol and ethambutol hydrochloride based on RP-HPLC-NQAD method | 浙江省食品药品检验研究院 | 2025-01-03 | — | — | CN | claimed |
| CN-118743705-B | Pharmaceutical composition and application thereof | 深圳大学 | 2024-11-15 | — | — | CN | claimed |
| US-20240366599-A1 | HUMAN EFFICACIOUS DOSE AND DOSAGE SCHEDULE OF SPR720 | SPERO THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | claimed |
| CN-118743705-A | Pharmaceutical composition and application thereof | 深圳大学 | 2024-10-08 | — | — | CN | claimed |
| EP-4422616-A1 | HUMAN EFFICACIOUS DOSE AND DOSAGE SCHEDULE OF SPR720 | Spero Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118159265-A | Human effective dose and dose regimen for SPR720 | 斯派尔治疗有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| US-20230346770-A1 | COMBINATION OF BEDAQUILINE, ETHAMBUTOL AND A MACROLIDE IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIAL DISEASES | JANSSEN VACCINES & PREVENTION B.V. (NL) | 2023-11-02 | — | — | US | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20030147812-A1 | Device and methods for initiating chemical reactions and for the targeted delivery of drugs or other agents | DORNIER MEDTECH SYSTEMS GMBH. (DE) | 2003-08-07 | — | — | US | claimed |
| WO-2002087547-A1 | AN IMPROVED PROCESS FOR PREPARATION OF FOUR-DRUG ANTI-TUBERCULAR FIXED DOSE COMBINATION | LUPIN LIMITED (IN) | 2002-11-07 | — | — | WO | claimed |
| US-5948416-A | LEAVE ON SKIN CARE COMPOSITION; HYDROPHOBIC STRUCTURING AGENT; HYDROPHILIC CATIONIC SURFACTANT; ACTIVE COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-07 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5780049-A | Enhanced skin penetration system for improved topical delivery of drugs | RICHARDSON-VICKS INC. (US) | 1998-07-14 | — | — | US | claimed |
| US-5733572-A | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles | IMARX PHARMACEUTICAL CORP. (US) | 1998-03-31 | — | — | US | claimed |